SAM
BMRN icon

SEB Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SEB Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Buy
412,150
+118,873
+41% +$6.51M 0.09% 196
2026
Q1 		$16.6M Buy
+293,277
New +$17.1M 0.07% 230

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SEB Asset Management's BMRN Position: Q2 2026 in Review

SEB Asset Management increased its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, buying an estimated $6.51M and bringing the position to 412,150 shares worth $23.6M. The position accounts for 0.09% of the portfolio, ranked #196.

SEB Asset Management first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 526 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SEB Asset Management held 412,150 shares of BioMarin Pharmaceuticals worth $23.6M as of Q2 2026.
  • SEB Asset Management bought 118,873 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $6.51M.
  • BioMarin Pharmaceuticals made up 0.09% of SEB Asset Management's portfolio in Q2 2026, its #196 holding.
  • SEB Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 526 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.